To interrupt this process, CDK inhibitors have been developed for cancer treatment with the success of FDA-approved CDK4/6 inhibitors to treat certain types of hormone receptor-positive, HER2-negative breast cancers [30]. The gene discussed is ERBB2; the disease is breast carcinoma.